Cibus Inc(CBUS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:00 PM ET (Korea 11/7 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.65 | Insider Own | 38.65% | Shs Outstand | 76.4M | Perf Week | -8.53% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | 24.8% | Insider Trans | - | Shs Float | 46.9M | Perf Month | -25.79% |
| Enterprise Value | 0.36B | PEG | - | EPS next Q | -0.2 | Inst Own | 25.09% | Short Float | 6.67% | Perf Quarter | -38.22% |
| Income | -0.10B | P/S | 20.73 | EPS this Y | 69.54% | Inst Trans | -6.32% | Short Ratio | 27.76 | Perf Half Y | -18.06% |
| Sales | 0.00B | P/B | 6.09 | EPS next 5Y | 51.36% | ROA | -29.77% | Short Interest | 3.13M | Perf YTD | -32.18% |
| Book/sh | 0.19 | P/C | 4.41 | EPS past 3/5Y | 46.72% 46.96% | ROE | -225.93% | 52W High | -71.84% ($4.19) | Perf Year | -5.98% |
| Cash/sh | 0.27 | P/FCF | - | Sales past 3/5Y | 185.12% -31.34% | ROIC | -33.02% | 52W Low | 8.26% ($1.09) | Perf 3Y | -89.19% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 84.17% | Gross Margin | -17.97% | Volatility(W/M) | 12.43% 9.16% | Perf 5Y | -99.35% |
| Dividend TTM | - | EV/Sales | 81.84 | Sales Y/Y TTM | -10.3% | Oper. Margin | -1240.9% | ATR (14) | 0.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.62 | EPS Q/Q | 52.67% | Profit Margin | -2258.89% | RSI (14) | 36.34 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.62 | Sales Q/Q | 6.54% | SMA20 | -11.23% ($1.33) | Beta | 1.65 | Target Price | $14.33 |
| Payout | - | Debt/Eq | 19.34 | Earnings | 2026/11/12 | SMA50 | -20.28% ($1.48) | Rel Volume | 1.45 | Prev Close | $1.14 |
| Employees | 118 | LT Debt/Eq | 19.09 | EPS/Sales Surpr. | -52.63% -41.67% | SMA200 | -35.63% ($1.83) | Avg Volume(3M) | 0.11M | Price | $1.18 |
| IPO | 2017/7/20 | Option/Short | Yes/Yes | Trades | 512 | Volume | 163,314 | Change | 3.51% |
🌱 Cibus (CBUS) is an agricultural biotechnology company that develops crop traits using gene editing technology. It operates a business model that leverages its proprietary trait development platform to create commercial traits such as herbicide tolerance, which are then licensed to seed companies. The company is expanding its trait pipeline around key crops including rice and canola, and is headquartered in the United States.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded more than usual. That is 145% of its average volume.
Next earnings report: November 12
5 days to go.
CBUS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +69.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,073. Peers typically go for $917.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.3%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 25.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #365 of 597 in the industry
Based on market cap of $90M.
FAQ
What kind of company is CBUS?
CBUS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CBUS?
The market cap of CBUS is approximately $90M, ranking 4,533 within its sector.
What is the 52-week high and low for CBUS?
CBUS has recorded a 52-week high of $4.19 and a low of $1.09.
